Avalo Therapeutics CFO Sullivan sells over $1.4m in stock

Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics (NASDAQ:AVTX), sold a significant amount of company stock on August 17 and 18, 2026, totaling approximately $1.45 million. These sales followed the exercise of stock options and were executed under a Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling shares. The transactions come as the stock trades at $19.34, near its 52-week high of $24.27, though InvestingPro analysis suggests the stock is overvalued relative to its Fair Value estimate. According to an InvestingPro tip, the stock has delivered a strong 114% return over the last year, though it has taken a hit over the last week. Investors can access 14 additional ProTips and comprehensive financial metrics on InvestingPro.

On August 17, Mr. Sullivan sold 37,945 shares of common stock for a total of $753,333. These shares were sold at prices ranging from $19.16 to $20.02 per share. On the same day, he sold an additional 3,749 shares at prices ranging from $19.70 to $20.02. The following day, August 18, he sold 31,031 shares at prices ranging from $20.00 to $20.265. The combined sales of these 34,780 shares (3,749 + 31,031) amounted to $697,085. In total, Mr. Sullivan disposed of 72,725 shares over the two days.

Prior to these sales, Mr. Sullivan acquired shares through the exercise of stock options. On August 17, he acquired 37,945 shares at an exercise price of $9.88 per share, totaling $374,896. On the same day, he acquired another 2,876 shares, and on August 18, he acquired 31,031 shares, both at $9.88 per share. The combined acquisitions of these 33,907 shares (2,876 + 31,031) totaled $335,001. The stock options, which allow the right to buy shares at $9.88, vest 25% on March 28, 2025, and 1/36 monthly thereafter, subject to his continued service.

Following these reported transactions, Christopher Ryan Sullivan directly beneficially owns 39,900 shares of Avalo Therapeutics common stock.

In other recent news, Avalo Therapeutics has been added to the Russell 2000 and Russell 3000 indexes, reflecting its position among the largest publicly traded companies in the U.S. This inclusion is effective after the close of U.S. equity markets today. In analyst developments, Cantor Fitzgerald reiterated an Overweight rating on Avalo Therapeutics, focusing on the company’s Phase 2 data for abdakibart in hidradenitis suppurativa. Additionally, Leerink initiated coverage with an Outperform rating and set a price target of $38.00.

The company also announced the appointment of Ron Philip to its board of directors, where he will serve until the 2027 Annual Meeting of Stockholders. Philip brings over 30 years of experience in the biopharmaceutical sector and will join the Compensation Committee and the Science, Development and Commercial Advisory Committee. These recent developments highlight Avalo Therapeutics’ strategic moves and ongoing progress in its business operations.